1
|
Jusue-Torres I, Tiv R, Ricarte-Filho JC, Mallisetty A, Contreras-Vargas L, Godoy-Calderon MJ, Khaddour K, Kennedy K, Valyi-Nagy K, David O, Menchaca M, Kottorou A, Koutras A, Dimitrakopoulos F, Abdelhady KM, Massad M, Rubinstein I, Feldman L, Stewart J, Shimamura T, Danilova L, Hulbert A. Myo1e overexpression in lung adenocarcinoma is associated with increased risk of mortality. Sci Rep 2023; 13:4107. [PMID: 36914720 PMCID: PMC10011530 DOI: 10.1038/s41598-023-30765-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2022] [Accepted: 02/28/2023] [Indexed: 03/16/2023] Open
Abstract
This study aims to perform a comprehensive genomic analysis to assess the influence of overexpression of MYO1E in non-small cell lung carcinoma (NSCLC) and whether there are differences in survival and mortality risk in NSCLC patients depending on both DNA methylation and RNA expression of MYO1E. The DNA methylation probe cg13887966 was inversely correlated with MYO1E RNA expression in both LUAD and LUSC subpopulations showing that lower MYO1E RNA expression was associated with higher MYO1E DNA methylation. Late stages of lung cancer showed significantly lower MYO1E DNA methylation and significantly higher MYO1E RNA expression for LUAD but not for LUSC. Low DNA methylation as well as high RNA expression of MYO1E are associated with a shorter median survival time and an increased risk of mortality for LUAD, but not for LUSC. This study suggests that changes in MYO1E methylation and expression in LUAD patients may have an essential role in lung cancer's pathogenesis. It shows the utility of MYO1E DNA methylation and RNA expression in predicting survival for LUAD patients. Also, given the low normal expression of MYO1E in blood cells MYO1E DNA methylation has the potential to be used as circulating tumor marker in liquid biopsies.
Collapse
Affiliation(s)
| | - Richies Tiv
- Department of Surgery, University of Illinois at Chicago College of Medicine, Chicago, IL, USA
| | | | - Apurva Mallisetty
- Department of Surgery, University of Illinois at Chicago College of Medicine, Chicago, IL, USA
| | - Leglys Contreras-Vargas
- Department of Surgery, University of Illinois at Chicago College of Medicine, Chicago, IL, USA
| | | | - Karam Khaddour
- Division of Hematology Oncology, University of Illinois at Chicago College of Medicine, Chicago, IL, USA
| | - Kathleen Kennedy
- Division of Hematology Oncology, University of Illinois at Chicago College of Medicine, Chicago, IL, USA
| | - Klara Valyi-Nagy
- Department of Pathology, University of Illinois at Chicago College of Medicine, Chicago, IL, USA
| | - Odile David
- Department of Pathology, University of Illinois at Chicago College of Medicine, Chicago, IL, USA
| | - Martha Menchaca
- Department of Radiology, University of Illinois at Chicago College of Medicine, Chicago, IL, USA
| | - Anastasia Kottorou
- Molecular Oncology Laboratory, Division of Oncology, Medical School, University of Patras, Patras, Greece
| | - Angelos Koutras
- Molecular Oncology Laboratory, Division of Oncology, Medical School, University of Patras, Patras, Greece
| | - Foteinos Dimitrakopoulos
- Molecular Oncology Laboratory, Division of Oncology, Medical School, University of Patras, Patras, Greece
| | | | - Malek Massad
- Division of Cardiothoracic Surgery, University of Illinois at Chicago College of Medicine, Chicago, IL, USA
| | - Israel Rubinstein
- Medical and Research Services, Jesse Brown VA Medical Center, Chicago, IL, USA
- Division of Pulmonary, Critical Care, Sleep, and Allergy Medicine, University of Illinois at Chicago College of Medicine, Chicago, IL, USA
| | - Lawrence Feldman
- Division of Hematology Oncology, University of Illinois at Chicago College of Medicine, Chicago, IL, USA
- Medical and Research Services, Jesse Brown VA Medical Center, Chicago, IL, USA
| | - John Stewart
- Department of Surgery, University of Illinois at Chicago College of Medicine, Chicago, IL, USA
- Section of Surgical Oncology, Department of Surgery, Louisiana State University, New Orleans, LA, USA
| | - Takeshi Shimamura
- Cancer Center, University of Illinois at Chicago, Chicago, IL, USA
- Division of Cardiothoracic Surgery, University of Illinois at Chicago College of Medicine, Chicago, IL, USA
| | - Ludmila Danilova
- Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA
- Laboratory of Systems Biology and Computational Genetics, Vavilov Institute of General Genetics, Russian Academy of Sciences, Moscow, Russia
| | - Alicia Hulbert
- Cancer Center, University of Illinois at Chicago, Chicago, IL, USA.
- Medical and Research Services, Jesse Brown VA Medical Center, Chicago, IL, USA.
- Department of Surgery, University of Illinois College of Medicine, 909 South Wolcott Ave, COMRB Suite 5140, Chicago, IL, 60612, USA.
| |
Collapse
|
2
|
Kottorou A, Dimitrakopoulos FI, Diamantopoulou G, Kalofonou F, Stavropoulos M, Thomopoulos K, Makatsoris T, Koutras A, Kalofonos H. Small Extracellular Vesicles (sEVs) Biogenesis Molecular Players Are Associated with Clinical Outcome of Colorectal Cancer Patients. Cancers (Basel) 2023; 15:cancers15061685. [PMID: 36980570 PMCID: PMC10046180 DOI: 10.3390/cancers15061685] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2023] [Revised: 03/01/2023] [Accepted: 03/04/2023] [Indexed: 03/12/2023] Open
Abstract
A growing number of studies have shed light on the role of small extracellular vesicles (sEVs), including exosomes, in colorectal cancer (CRC). Available data regarding the clinical significance of molecular players in CRC, implicated in sEVs biogenesis, is limited. In this study, we assessed the expression of the most important genes which are implicated in sEVs biogenesis and their association with sEVs plasma levels, investigated with a double sandwich ELISA assay, as well as with the clinical outcome of patients with CRC. Our study shows that RAB27A, RAB27B, RAB2B, and RAB3B mRNA levels were lower in tumor tissues compared to tumor adjacent, non-malignant tissues (p < 0.001, p = 0.009, p = 0.011, and p < 0.001, respectively). In addition, high tumor expression of RAB27A, RAB27B, RAB9A, RAB11B, and STX1A was favorable of a 5-year survival (p = 0.038, p = 0.015, p = 0.008, p = 0.002, and p = 0.028, respectively). Furthermore, patients with adenomas had lower overall plasma sEVs concentrations, compared to healthy volunteers (p = 0.026), while no statistically significant differences were observed in the overall or tumor-derived plasma sEVs concentration (p = 0.885 and p = 0.330, respectively) of CRC patients. In conclusion, sEVs biogenesis has a potentially significant role in CRC, with RAB27A, RAB27B, RAB9A, RAB11B, and STX1A having a promising role in survival outcomes.
Collapse
Affiliation(s)
- Anastasia Kottorou
- Division of Oncology, Department of Medicine, University Hospital of Patras, 26504 Rio, Greece
- Molecular Oncology Laboratory, Medical School, University of Patras, 26504 Rio, Greece
| | - Foteinos-Ioannis Dimitrakopoulos
- Division of Oncology, Department of Medicine, University Hospital of Patras, 26504 Rio, Greece
- Molecular Oncology Laboratory, Medical School, University of Patras, 26504 Rio, Greece
- Correspondence: (F.-I.D.); (H.K.); Tel.: +30-2610-997669 (H.K.)
| | | | - Foteini Kalofonou
- Department of Oncology, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK
| | | | | | - Thomas Makatsoris
- Division of Oncology, Department of Medicine, University Hospital of Patras, 26504 Rio, Greece
- Molecular Oncology Laboratory, Medical School, University of Patras, 26504 Rio, Greece
| | - Angelos Koutras
- Division of Oncology, Department of Medicine, University Hospital of Patras, 26504 Rio, Greece
- Molecular Oncology Laboratory, Medical School, University of Patras, 26504 Rio, Greece
| | - Haralabos Kalofonos
- Division of Oncology, Department of Medicine, University Hospital of Patras, 26504 Rio, Greece
- Molecular Oncology Laboratory, Medical School, University of Patras, 26504 Rio, Greece
- Correspondence: (F.-I.D.); (H.K.); Tel.: +30-2610-997669 (H.K.)
| |
Collapse
|
3
|
Dimitrakopoulos FI, Mountzios G, Christopoulos P, Papastergiou T, Elshiaty M, Daniello L, Zervas E, Agelaki S, Samantas E, Nikolaidi A, Athanasiadis I, Baka S, Syrigos K, Christopoulou A, Lianos E, Samitas K, Tsoukalas N, Perdikouri EI, Oikonomopoulos G, Kottorou A, Kalofonou F, Makatsoris T, Koutras A, Megalooikonomou V, Kalofonos H. Validation of Patras Immunotherapy Score model for prediction and prognosis of patients with advanced NSCLC treated with nivolumab or pembrolizumab: results from a European multicentre study. Ther Adv Med Oncol 2022; 14:17588359221122728. [PMID: 36105886 PMCID: PMC9465562 DOI: 10.1177/17588359221122728] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2021] [Accepted: 08/10/2022] [Indexed: 11/18/2022] Open
Abstract
Background: Recently, the Patras Immunotherapy Score (PIOS) has been developed to
estimate the survival benefit of patients with advanced non-small-cell lung
cancer (aNSCLC) treated with nivolumab or pembrolizumab. The aim of this
study was to validate the clinical value of PIOS in an external cohort of
aNSCLC patients. Methods: PIOS is a baseline formula produced by the combination of performance status,
body mass index, age and line of treatment. In this multicentre study, 626
patients with confirmed NSCLC pathology, who had been treated with nivolumab
or pembrolizumab, as well as 444 patients with aNSCLC, who had been managed
with chemotherapy alone, were retrospectively enrolled. Predictive and
prognostic values of PIOS were finally evaluated. Results: Patients treated with immunotherapy and higher PIOS score had an improved
progression-free survival not only in univariate [hazard ratio (HR) = 0.621,
p = 0.001], but also in multivariable analysis (HR =
0.651, p = 0.003). In addition, improved overall survival
with increasing PIOS score was also observed (HR = 0.608, p
< 0.001) with this association remaining statistically significant after
adjusting for programmed-cell death ligand 1 (PD-L1) expression (HR = 0.620,
p < 0.001). In addition, patients with disease
progression (PD) had lower scores compared to those with stable disease
(SD), partial response (PR) or complete response (CR) in a two-tier model
(p < 0.001) as well as in a four-tier model (PD, SD,
PR and CR; p < 0.001). Prognostic significance of PIOS
score also persisted using a binary logistic regression analysis, adjusted
for disease stage and PD-L1 status (p = 0.002, odds ratio:
0.578). Contrarily, PIOS had no prognostic significance in the chemotherapy
group; however, upon combined analysis of the two cohorts, PIOS was found to
have a significant interaction with the type of treatment (HR = 0.066 with
p < 0.001), confirming its predictive value for
immunotherapy. Conclusions: This study provides further validation of PIOS in aNSCLC patients treated
with anti-PD-1 monotherapy.
Collapse
Affiliation(s)
- Foteinos-Ioannis Dimitrakopoulos
- Division of Oncology, Department of Medicine, University Hospital of Patras, Patras, GreeceMolecular Oncology Laboratory, Department of Medicine, University of Patras, Patras, Greece
| | - Giannis Mountzios
- Second Department of Medical Oncology and Clinical Trials Unit, Henry Dunant Hospital Center, Athens, Greece
| | - Petros Christopoulos
- Department of Thoracic Oncology, Thoraxklinik at Heidelberg University Hospital, Heidelberg, GermanyTranslational Lung Research Center Heidelberg, Heidelberg, Germany
| | - Thomas Papastergiou
- Computer Engineering and Informatics Department, University of Patras, Patras, Greece
| | - Mariam Elshiaty
- Department of Thoracic Oncology, Thoraxklinik at Heidelberg University Hospital, Heidelberg, GermanyTranslational Lung Research Center Heidelberg, Heidelberg, Germany
| | - Lea Daniello
- Department of Thoracic Oncology, Thoraxklinik at Heidelberg University Hospital, Heidelberg, GermanyTranslational Lung Research Center Heidelberg, Heidelberg, Germany
| | - Elefterios Zervas
- Seventh Respiratory Medicine Department and Asthma Center, Athens Chest Hospital Sotiria, Athens, Greece
| | - Sofia Agelaki
- Department of Medical Oncology, University General Hospital, Heraklion, Greece
| | - Epaminondas Samantas
- Third Department of Medical Oncology, Agii Anargiri Cancer Hospital, Athens, Greece
| | | | | | - Sofia Baka
- Oncology Department, Interbalkan European Medical Center, Thessaloniki, Greece
| | - Konstantinos Syrigos
- Oncology Unit, The Third Department of Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece
| | | | - Evangelos Lianos
- Division of Medical Oncology and Hematopoietic Cell Transplant Unit, Department of Medicine, "Metaxa" Cancer Hospital, Piraeus, Greece
| | - Konstantinos Samitas
- Seventh Respiratory Medicine Department and Asthma Center, Athens Chest Hospital Sotiria, Athens, Greece
| | | | | | | | - Anastasia Kottorou
- Division of Oncology, Department of Medicine, University Hospital of Patras, Patras, GreeceMolecular Oncology Laboratory, Department of Medicine, University of Patras, Patras, Greece
| | - Foteini Kalofonou
- Department of Oncology, Imperial College NHS Healthcare Trust, Charing Cross Hospital, London, UK
| | - Thomas Makatsoris
- Division of Oncology, Department of Medicine, University Hospital of Patras, Patras, GreeceMolecular Oncology Laboratory, Department of Medicine, University of Patras, Patras, Greece
| | - Angelos Koutras
- Division of Oncology, Department of Medicine, University Hospital of Patras, Patras, GreeceMolecular Oncology Laboratory, Department of Medicine, University of Patras, Patras, Greece
| | | | - Haralabos Kalofonos
- Division of Oncology, Department of Medicine, University Hospital of Patras, GreeceMolecular Oncology Laboratory, Department of Medicine, University of Patras, Rion-Patras, Patras, Achaia 26504, Greece
| |
Collapse
|
4
|
Dimitrakopoulos FI, Christopoulos P, Elshiaty M, Daniello L, Pyrousis I, Kottorou A, Makatsoris T, Kalofonos H, Koutras A. EP08.01-072 Clinical Value of Patras Immunotherapy Score (PIOS) Formula in Patients With Advanced NSCLC Treated With Immunotherapy/Chemotherapy. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.644] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
5
|
Dimitrakopoulos FI, Christopoulos P, Elshiaty M, Daniello L, Pyrousis I, Kottorou A, Makatsoris T, Kalofonos C, Koutras A. 1091P Predictive and prognostic value of Patras Immunotherapy Score (PIOS) in patients with advanced NSCLC treated with immunotherapy/chemotherapy combination. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1216] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
6
|
Kottorou A, Dimitrakopoulos FI, Tsezou A. Non-coding RNAs in cancer-associated cachexia: clinical implications and future perspectives. Transl Oncol 2021; 14:101101. [PMID: 33915516 PMCID: PMC8100623 DOI: 10.1016/j.tranon.2021.101101] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2021] [Revised: 03/31/2021] [Accepted: 04/11/2021] [Indexed: 12/18/2022] Open
Abstract
Cachexia is a multifactorial syndrome characterized by skeletal muscle loss, with or without adipose atrophy, irreversible through nutritional support, in the context of systemic inflammation and metabolic disorders. It is mediated by inflammatory reaction and affects almost 50% of all cancer patients, due to prominent systemic inflammation associated with the disease. The comprehension of the molecular mechanisms that are implicated in cancer cachexia sheds light on its pathogenesis and lays the foundations for the discovery of new therapeutic targets and biomarkers. Recently, ncRNAs, like microRNAs as well as lncRNAs and circRNAs seem to regulate pathways that are implicated in cancer cachexia pathogenesis, as it has been observed in animal models and in cancer cachexia patients, highlighting their therapeutic potential. Moreover, increasing evidence highlights the involvement of circulating and exosomal ncRNAs in the activation and maintenance of systemic inflammation in cancer and cancer-associated cachexia. In that context, the present review focuses on the clinical significance of ncRNAs in cancer-associated cachexia.
Collapse
Affiliation(s)
- Anastasia Kottorou
- Molecular Oncology Laboratory, Division of Oncology, Medical School, University of Patras, 26504, Rio, Greece
| | | | - Aspasia Tsezou
- Laboratory of Biology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Biopolis, 41500, Larissa, Greece; Laboratory of Cytogenetics and Molecular Genetics, Faculty of Medicine, School of Health Sciences, University of Thessaly, Biopolis, 41500, Larissa, Greece.
| |
Collapse
|
7
|
Kottorou A, Dimitrakopoulos F, Antonacopoulou A, Makatsoris T, Stavropoulos M, Koutras A, Kalofonos H. P-224 Expression of major components of the exosome biogenesis pathway is deregulated in colorectal cancer and associated with clinical outcome: Preliminary results from an association study. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.05.278] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
8
|
Dimitrakopoulos FI, Kottorou A, Tzezou A. Endocrine resistance and epigenetic reprogramming in estrogen receptor positive breast cancer. Cancer Lett 2021; 517:55-65. [PMID: 34077785 DOI: 10.1016/j.canlet.2021.05.030] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2021] [Revised: 05/08/2021] [Accepted: 05/25/2021] [Indexed: 02/07/2023]
Abstract
Despite the enormous advances during the last three decades, breast cancer continues to be the most frequent type of cancer as well as one of the most frequent cancer-related causes of death in women. Therapeutic management of patients with hormone receptor-positive breast cancer becomes very often a challenge, since de novo or acquired resistance deprives a significant percentage of the patients from the clinical benefit of the well-tolerated hormone therapy. Several molecular mechanisms are implicated in resistance to endocrine therapy, including changes in hormone receptor signaling, activation of parallel signaling pathways, modifications of cell cycle regulators, activation of different transcription factors as well as changes in stem cells activity. In addition, a growing number of studies supports the pivotal role of epigenetic changes not only in the initiation and progression of breast cancer, but also in resistance to endocrine therapy. These changes refer to DNA methylation, histone post-translational modifications as well as to ncRNAs alterations. In this review, we provide an overview of epigenetic mechanisms underlying the endocrine resistance focusing exclusively on breast cancer patients.
Collapse
Affiliation(s)
- Foteinos-Ioannis Dimitrakopoulos
- Molecular Oncology Laboratory, Medical School of Patras, University of Patras, 26500, Patras, Greece; Division of Oncology, University Hospital of Patras, 26500, Patras, Greece
| | - Anastasia Kottorou
- Molecular Oncology Laboratory, Medical School of Patras, University of Patras, 26500, Patras, Greece; Division of Oncology, University Hospital of Patras, 26500, Patras, Greece
| | - Aspasia Tzezou
- Laboratory of Biology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Biopolis, 41500, Larissa, Greece; Laboratory of Cytogenetics and Molecular Genetics, Faculty of Medicine, School of Health Sciences, University of Thessaly, Biopolis, 41500, Larissa, Greece.
| |
Collapse
|
9
|
Liu B, Ricarte Filho J, Mallisetty A, Villani C, Kottorou A, Rodgers K, Chen C, Ito T, Holmes K, Gastala N, Valyi-Nagy K, David O, Gaba RC, Ascoli C, Pasquinelli M, Feldman LE, Massad MG, Wang TH, Jusue-Torres I, Benedetti E, Winn RA, Brock MV, Herman JG, Hulbert A. Detection of Promoter DNA Methylation in Urine and Plasma Aids the Detection of Non-Small Cell Lung Cancer. Clin Cancer Res 2020; 26:4339-4348. [PMID: 32430478 PMCID: PMC7442601 DOI: 10.1158/1078-0432.ccr-19-2896] [Citation(s) in RCA: 42] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2019] [Revised: 01/16/2020] [Accepted: 05/14/2020] [Indexed: 12/15/2022]
Abstract
PURPOSE Low-dose CT screening can reduce lung cancer-related mortality. However, CT screening has an FDR of nearly 96%. We sought to assess whether urine samples can be a source for DNA methylation-based detection of non-small cell lung cancer (NSCLC). EXPERIMENTAL DESIGN This nested case-control study of subjects with suspicious nodules on CT imaging obtained plasma and urine samples preoperatively. Cases (n = 74) had pathologic confirmation of NSCLC. Controls (n = 27) had a noncancer diagnosis. We detected promoter methylation in plasma and urine samples using methylation on beads and quantitative methylation-specific real-time PCR for cancer-specific genes (CDO1, TAC1, HOXA7, HOXA9, SOX17, and ZFP42). RESULTS DNA methylation at cancer-specific loci was detected in both plasma and urine, and was more frequent in patients with cancer compared with controls for all six genes in plasma and in CDO1, TAC1, HOXA9, and SOX17 in urine. Univariate and multivariate logistic regression analysis showed that methylation detection in each one of six genes in plasma and CDO1, TAC1, HOXA9, and SOX17 in urine were significantly associated with the diagnosis of NSCLC, independent of age, race, and smoking pack-years. When methylation was detected for three or more genes in both plasma and urine, the sensitivity and specificity for lung cancer diagnosis were 73% and 92%, respectively. CONCLUSIONS DNA methylation-based biomarkers in plasma and urine could be useful as an adjunct to CT screening to guide decision-making regarding further invasive procedures in patients with pulmonary nodules.
Collapse
Affiliation(s)
- Bin Liu
- Cancer Center, University of Illinois at Chicago, Chicago, Illinois
| | | | - Apurva Mallisetty
- Department of Surgery, University of Illinois at Chicago College of Medicine, Chicago, Illinois
| | - Cassandra Villani
- Department of Surgery, University of Illinois at Chicago College of Medicine, Chicago, Illinois
| | - Anastasia Kottorou
- Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland
- Clinical and Molecular Oncology Laboratory, Medical School, University of Patras, Patras, Greece
| | - Kristen Rodgers
- Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Chen Chen
- Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland
- Department of Thoracic Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China
| | - Tomoaki Ito
- Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland
- Department of Surgery, Juntendo University Shizuoka Hospital, Juntendo University School of Medicine, Shizuoka, Japan
| | - Kyla Holmes
- Cancer Center, University of Illinois at Chicago, Chicago, Illinois
| | - Nicole Gastala
- Department of Family Medicine, Mile Square Health Center, University of Illinois at Chicago College of Medicine, Chicago, Illinois
| | - Klara Valyi-Nagy
- Department of Pathology, University of Illinois at Chicago College of Medicine, Chicago, Illinois
| | - Odile David
- Department of Pathology, University of Illinois at Chicago College of Medicine, Chicago, Illinois
| | - Ron C Gaba
- Department of Radiology, University of Illinois at Chicago College of Medicine, Chicago, Illinois
| | - Christian Ascoli
- Department of Pulmonary, University of Illinois at Chicago College of Medicine, Chicago, Illinois
| | - Mary Pasquinelli
- Department of Pulmonary, University of Illinois at Chicago College of Medicine, Chicago, Illinois
| | - Lawrence E Feldman
- Department of Hematology and Oncology, University of Illinois at Chicago College of Medicine, Chicago, Illinois
| | - Malek G Massad
- Department of Surgery, University of Illinois at Chicago College of Medicine, Chicago, Illinois
| | - Tza-Huei Wang
- Department of Biomedical Engineering and Institute for Nano Biotechnology, The Johns Hopkins University, School of Medicine, Baltimore, Maryland
| | - Ignacio Jusue-Torres
- Department of Neurological Surgery, Loyola University Stritch School of Medicine, Maywood, Illinois
| | - Enrico Benedetti
- Department of Surgery, University of Illinois at Chicago College of Medicine, Chicago, Illinois
| | - Robert A Winn
- Cancer Center, University of Illinois at Chicago, Chicago, Illinois
- Department of Pulmonary, University of Illinois at Chicago College of Medicine, Chicago, Illinois
| | - Malcolm V Brock
- Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland
- Sidney Kimmel Cancer Center, Department of Oncology, The Johns Hopkins University, School of Medicine, Baltimore, Maryland
| | - James G Herman
- Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
| | - Alicia Hulbert
- Cancer Center, University of Illinois at Chicago, Chicago, Illinois.
- Department of Surgery, University of Illinois at Chicago College of Medicine, Chicago, Illinois
| |
Collapse
|
10
|
Dimitrakopoulos FID, Kourea E, Nasioulas G, Papadopoulou E, Nikolakopoulos A, Spyropoulou D, Kottorou A, Karatzas A, Kalofonos HP, Koutras A. Exceptional response to nivolumab of a heavily pre-treated patient with metastatic renal-cell cancer: from a case report to molecular investigation and future perspectives. Ther Adv Med Oncol 2020; 12:1758835920946152. [PMID: 32849917 PMCID: PMC7425249 DOI: 10.1177/1758835920946152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2020] [Accepted: 07/07/2020] [Indexed: 11/15/2022] Open
Abstract
Immunotherapy may result in long-lasting exceptional clinical responses, the molecular background of which is inadequately understood. Here, we present the case of a 63-year-old patient with a past medical history of renal cancer who relapsed many years later. Several treatment lines were administered prior to immunotherapy, which was administered in the ninth line, achieving complete remission which had lasted for more than 3 years. Genomic alterations, tumor mutational burden (TMB), and microsatellite instability as well as PD-L1, MLH1, MSH2, MSH6, PMS2, CD3, CD8, CD20, CD138, CD1a, and FoxP3 expression were assessed in primary and metastatic tumors. Primary and metastatic tumors were microsatellite stable with high TMB, while somatic mutations in MLH1 and TP53 genes were detected, respectively. Although the primary tumor was negative for PD-L1 expression, the lung metastasis was positive. Interestingly, metastasis displayed a dramatically increased infiltration by CD1a-positive dendritic cells in addition to increased CD3+ and CD8+ cytotoxic T cells. Increased infiltration of the metastatic tumor by CD1a+ antigen presenting cells warrants further investigation to assess its potential predictive value.
Collapse
Affiliation(s)
| | - Eleni Kourea
- Department of Pathology, School of Medicine, University of Patras, Patras, Greece
| | | | | | - Achilles Nikolakopoulos
- Department of Medicine, Medical School, Division of Oncology, University of Patras, Patras, Greece
| | - Despoina Spyropoulou
- Department of Radiation Oncology, Medical School, University of Patras, Patras, Greece
| | - Anastasia Kottorou
- Department of Medicine, Medical School, Division of Oncology, University of Patras, Patras, Greece
| | | | - Haralabos P. Kalofonos
- Department of Medicine, Medical School, Division of Oncology, University of Patras, Patras, Greece
| | - Angelos Koutras
- Department of Medicine, Medical School, Division of Oncology, University of Patras, Rion-Patras, 26504, Greece
| |
Collapse
|
11
|
Dimitrakopoulos FI, Nikolakopoulos A, Kottorou A, Kalofonou F, Liolis E, Frantzi T, Pyrousis I, Koutras A, Makatsoris T, Kalofonos H. PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) Inhibitors. Cancers (Basel) 2020; 12:E1257. [PMID: 32429368 PMCID: PMC7280986 DOI: 10.3390/cancers12051257] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2020] [Revised: 05/05/2020] [Accepted: 05/12/2020] [Indexed: 12/17/2022] Open
Abstract
Immunotherapy with immune checkpoint inhibitors (ICIs) has changed the therapeutic management of advanced non-small cell lung cancer (aNSCLC) over the last decade. However, there is an unmet need for clinically useful biomarkers in this patient subgroup. The aim of this study was to combine baseline clinical characteristics of aNSCLC patients, in the form of a scoring system, and to investigate its predictive and prognostic value in NSCLC patients treated with ICIs. A total of 112 patients with advanced (stages IIIA to IV) NSCLC, treated with nivolumab or pembrolizumab, were enrolled in this study. Patras Immunotherapy Score (PIOS) was developed based on four of the studied parameters (performance status (PS), body mass index (BMI), age, and lines of treatment (LOT), which were incorporated into our formula (PS × BMI/ LOT × age). PIOS score was strongly associated with best overall responses (BOR), with those patients having benefit/good response (stable disease (SD) or partial (PR) or complete response (CR), achieving a higher score compared to patients who developed progressive disease (PD) (p < 0.001). Furthermore, PIOS score was associated with progression-free survival (PFS), since high-score patients had longer PFS (p < 0.001, hazard ratio (HR) = 0.469). Moreover, PIOS was associated with post-immunotherapy overall survival (OS), with high-score patients having improved OS (log-rank p = 0.019). This study suggests that a combination of baseline parameters, which give rise to PIOS score, may predict the best response of NSCLC patients treated with anti-program cell death -1 (PD-1) monotherapy as well as it may have a potent prognostic value for PFS and post immunotherapy OS.
Collapse
Affiliation(s)
- Foteinos-Ioannis Dimitrakopoulos
- Division of Oncology, Department of Medicine, University Hospital of Patras, 26504 Rion, Greece; (F.-I.D.); (A.N.); (E.L.); (T.F.); (A.K.); (T.M.)
- Clinical and Molecular Oncology Laboratory, Medical School, University of Patras, 26504 Rion, Greece; (A.K.); (I.P.)
| | - Achilleas Nikolakopoulos
- Division of Oncology, Department of Medicine, University Hospital of Patras, 26504 Rion, Greece; (F.-I.D.); (A.N.); (E.L.); (T.F.); (A.K.); (T.M.)
| | - Anastasia Kottorou
- Clinical and Molecular Oncology Laboratory, Medical School, University of Patras, 26504 Rion, Greece; (A.K.); (I.P.)
| | | | - Elias Liolis
- Division of Oncology, Department of Medicine, University Hospital of Patras, 26504 Rion, Greece; (F.-I.D.); (A.N.); (E.L.); (T.F.); (A.K.); (T.M.)
| | - Theodora Frantzi
- Division of Oncology, Department of Medicine, University Hospital of Patras, 26504 Rion, Greece; (F.-I.D.); (A.N.); (E.L.); (T.F.); (A.K.); (T.M.)
| | - Ioannis Pyrousis
- Clinical and Molecular Oncology Laboratory, Medical School, University of Patras, 26504 Rion, Greece; (A.K.); (I.P.)
| | - Angelos Koutras
- Division of Oncology, Department of Medicine, University Hospital of Patras, 26504 Rion, Greece; (F.-I.D.); (A.N.); (E.L.); (T.F.); (A.K.); (T.M.)
| | - Thomas Makatsoris
- Division of Oncology, Department of Medicine, University Hospital of Patras, 26504 Rion, Greece; (F.-I.D.); (A.N.); (E.L.); (T.F.); (A.K.); (T.M.)
| | - Haralabos Kalofonos
- Division of Oncology, Department of Medicine, University Hospital of Patras, 26504 Rion, Greece; (F.-I.D.); (A.N.); (E.L.); (T.F.); (A.K.); (T.M.)
- Clinical and Molecular Oncology Laboratory, Medical School, University of Patras, 26504 Rion, Greece; (A.K.); (I.P.)
| |
Collapse
|
12
|
Antonacopoulou A, Kottorou A, Koutras A, Dimitrakopoulos FI, Makatsoris T, Kalofonos HP. Abstract 1343: SNPs in the NFKB alternative pathway genes CD40, BAFFR and LTβR in CRC. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-1343] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
We sought to assess the role of single nucleotide polymorphisms (SNPs) in genes of the alternative NF-KB pathway, important in regulating different aspects of immune functions in colorectal cancer (CRC). The study comprised DNA samples from 418 patients with CRC and 299 age-matched healthy individuals. Genotyping was performed with real time PCR followed by high resolution melt curve analysis for the following SNPs: CD40 rs1883832 (C/T), BAFFR rs7290134 (A/G), LTβR rs10849448 (A/G). Genotypes of random samples were confirmed by sequencing. Genotype frequencies differed between CRC and healthy individuals for CD40 rs1883832 and LTβR rs10849448 (p = 0.001 and p = 0.016, respectively) but were similar for BAFFR rs7290134. The LTβR rs10849448 G allele was more frequent in CRC patients compared to healthy controls and increased risk for CRC by 61% (p = 0.024). Moreover, the G allele was found more frequently in stage D patients compared to stages A and C while the A allele was more prevalent in stage B patients (p = 0.007). Additionally, most patients with grade III tumors were G allele carriers whereas the majority of grade I tumors were AA homozygotes (p = 0.019). The CD40 rs1883832 T allele was less frequent in CRC patients and reduced risk for CRC by 71% (p = 0.027). The CD40 rs1883832 SNP proved to be a prognostic factor for PFS with the CC individuals displaying a longer PFS compared to T carriers (p = 0.045). The BAFFR rs7290134 SNP was independent of all clinical parameters evaluated. Primary site was independent of genotypes for all three SNPs. SNPs within genes of receptors of the NF-KB alternative pathway, CD40 rs1883832 and LTβR rs10849448, influence PFS and risk for CRC development. Additionally, particular genotypes correlated with stage and grade.
Citation Format: Anna Antonacopoulou, Anastasia Kottorou, Angelos Koutras, Foteinos-Ioannis Dimitrakopoulos, Thomas Makatsoris, Haralabos P. Kalofonos. SNPs in the NFKB alternative pathway genes CD40, BAFFR and LTβR in CRC [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1343.
Collapse
|
13
|
Dimitrakopoulos FI, Antonacopoulou A, Kottorou A, Tzelepi V, Panagopoulos N, Kalofonou M, Dougenis D, Koutras A, Makatsoris T, Kalofonos H. Genetic variation of lymphotoxin beta receptor (LTβR) rs10849448 (A/G) is associated with risk for lung cancer and metastatic spread to adrenals. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz073.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
14
|
Dimitrakopoulos FI, Antonacopoulou A, Kottorou A, Marousi S, Koukourikou I, Scopa C, Dougenis D, Tzelepi V, Kalofonos H. Association of the rs1883832 variant of CD40 with NSCLC risk and overall survival. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy303.036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
15
|
Lerner L, Zheng L, Kottorou A, Chen C, Ito T, Rodgers K, Lee B, Winn R, Benedetti E, Wang TH, Brock MV, Herman JG, Hulbert A. Abstract 3308: Urine epigenetic biomarkers for NSCLC diagnosis. Cancer Res 2018. [DOI: 10.1158/1538-7445.am2018-3308] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose:
The National Lung Cancer Screening Trial showed mortality reduction on patients with NSCLC by the use of Low-dose CT screening. The study exhibits an unreasonably high false positive rate of 96.6%, which can to lead to significant morbidity and mortality from unnecessary tests. This study aim to determine if methylated promoter regions of a panel of genes that are correlated with Non-Small Cell Lung Cancer can be detected in urine from patients with lung cancer versus those without.
Materials and Methods:
We conducted a prospective case-control study recruiting subjects from the Lung Cancer Spore Trial. Urine and pre-operative CT scans were obtained from all patients. We processed the urine using the Methylation on Beads assay to isolate and bisulfite treat circulating DNA and then employed Quantitative Methylation Specific Real-Time PCR to detect promoter methylation status of the genes: CDO1, TAC1, HOXA7, HOXA9, SOX17 and ZFP42. Sensitivity, specificity, PPV and NPV values were calculated for each gene methylation status.
Results:
34 patients were studied, including 23 patients with NSCLC and 11 patients with benign non-cancerous lesions. The sensitivity, specificity, PPV and NPV values for lung cancer detection in urine are shown in Table 1. Sensitivities ranged 43-96%, Specificities 64-91%, PPV 71-100% and NPV 40-67%. Promoter methylation of the gene panel CDO1, TAC1, HOXA7, HOXA9, SOX17 and ZPF42 has a 78% sensitivity, 91% specificity, 95% PPV and 67% NPV for lung cancer detection.
Conclusion:
Our study suggests that urine can provide a highly sensitive and specific non-invasive route for lung cancer detection. These results are very promising and could potentially reduce unnecessary morbidity and mortality in people undergoing screening for NSCLC by use of a non-invasive method that could be more accessible on primary care centers. However, further studies and validation with larger sample sizes and different populations are necessary before its application to clinical practice.
Patients with positive gene methylation from urine samples and its accuracy for NSCLC detection.Cancer (n=23)Cancer (n=23)Control (n=11)Control (n=11)nSensitivitynSpecificityPPVNPVCDO114611919353TAC11565010010058SOX1716704648050HOXA711483737940HOXA910431919143ZPF4222969187167Panel of genes18781919567
Citation Format: Lane Lerner, Lily Zheng, Anastasia Kottorou, Chen Chen, Tomoaki Ito, Kristen Rodgers, Beverly Lee, Robert Winn, Enrico Benedetti, Tza- Huei Wang, Malcolm V. Brock, James G. Herman, Alicia Hulbert. Urine epigenetic biomarkers for NSCLC diagnosis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 3308.
Collapse
Affiliation(s)
- Lane Lerner
- 1University of Illinois at Chicago, Chicago, IL
| | - Lily Zheng
- 1University of Illinois at Chicago, Chicago, IL
| | | | - Chen Chen
- 3The Second Xiangya Hospital CSU, Xiangya, China
| | - Tomoaki Ito
- 4Johns Hopkins University School of Medicine, Baltimore, MD
| | | | - Beverly Lee
- 4Johns Hopkins University School of Medicine, Baltimore, MD
| | - Robert Winn
- 1University of Illinois at Chicago, Chicago, IL
| | | | - Tza- Huei Wang
- 5Johns Hopkins Whiting School of Engineering, Baltimore, MD
| | | | - James G. Herman
- 6University of Pittsburgh School of Medicine, Pittsburgh, PA
| | | |
Collapse
|
16
|
Antonacopoulou A, Kottorou A, Tzelepi V, Dimitrakopoulos F, Makatsoris T, Koutras A, Kalofonos H. PO-513 The alternative NF-κB pathway in colorectal cancer. from genetic polymorphisms through mRNA to protein levels. ESMO Open 2018. [DOI: 10.1136/esmoopen-2018-eacr25.1014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
17
|
Kottorou A, Sirinian C, Dimitrakopoulos F, Antonacopoulou A, Kalofonos H. PO-112 The role of transcribed ultraconserved regions Uc160 and Uc346 in colorectal cancer progression. ESMO Open 2018. [DOI: 10.1136/esmoopen-2018-eacr25.153] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
18
|
Kottorou A, Sirinian C, Dimitrakopoulos F, Antonacopoulou A, Makatsoris T, Kalofonos H. Transcribed ultraconserved regions Uc160 and Uc346 in colon cancer progression. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.193] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
19
|
Dimitrakopoulos FI, Tzelepi V, Kottorou A, Antonacopoulou A, Koutras A, Makatsoris T, Kalofonos H. Clinical significance of the expression of membrane receptors of the alternative nuclear factor-kappaB pathway in non-small cell lung cancer. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx390.063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
20
|
Kottorou A, Antonacopoulou A, Dimitrakopoulos FI, Diamantopoulou G, Theodorakopoulos T, Oikonomou C, Koukourikou I, Dalla D, Karatasou P, Katsakoulis E, Koutras A, Makatsoris T, Stavropoulos M, Thomopoulos K, Kalofonos H. Diagnostic value of methylation status of T-UCRs for colorectal cancer. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw370.118] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
21
|
Dimitrakopoulos F, Antonacopoulou A, Kottorou A, Maroussi S, Panagopoulos N, Scopa C, Koutras A, Makatsoris T, Dougenis D, Kalofonos H. NF-κB2 genetic variants (rs7897947 and rs12769316) are strongly correlated with the survival of NSCLC patients. Eur J Cancer 2016. [DOI: 10.1016/s0959-8049(16)61724-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
22
|
Dimtrakopoulos FID, Kottorou A, Yang A, Rodgers K, Baylin S, Hulbert A, Brock M. Correlation of exosome concentrations in the plasma of lung cancer patients with disease stage. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.e23016] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Fotinos-Ioannis D. Dimtrakopoulos
- Johns Hopkins University School of Medicine, Baltimore, MD; Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - Anastasia Kottorou
- Johns Hopkins University School of Medicine, Baltimore, MD; Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - Andrew Yang
- Johns Hopkins University School of Medicine, Baltimore, MD; Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - Kristen Rodgers
- Johns Hopkins University School of Medicine, Baltimore, MD; Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - Stephen Baylin
- Johns Hopkins University School of Medicine, Baltimore, MD; Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - Alicia Hulbert
- Johns Hopkins University School of Medicine, Baltimore, MD; Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - Malcolm Brock
- Johns Hopkins University School of Medicine, Baltimore, MD; Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| |
Collapse
|
23
|
Klavdianou K, Liossis SN, Papachristou DJ, Theocharis G, Sirinian C, Kottorou A, Filippopoulou A, Andonopoulos AP, Daoussis D. Decreased Serotonin Levels and Serotonin-Mediated Osteoblastic Inhibitory Signaling in Patients With Ankylosing Spondylitis. J Bone Miner Res 2016; 31:630-9. [PMID: 26420546 DOI: 10.1002/jbmr.2724] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/04/2015] [Revised: 09/23/2015] [Accepted: 09/28/2015] [Indexed: 12/17/2022]
Abstract
Evidence suggests that serotonin is an inhibitor of bone formation. We aimed to assess: 1) serum serotonin levels in patients with ankylosing spondylitis (AS), a prototype bone-forming disease, compared with patients with rheumatoid arthritis (RA) and healthy subjects; 2) the effect(s) of TNFα blockers on serum serotonin levels in patients with AS and RA; and 3) the effect(s) of serum of AS patients on serotonin signaling. Serum serotonin levels were measured in 47 patients with AS, 28 patients with RA, and 40 healthy subjects by radioimmunoassay; t test was used to assess differences between groups. The effect of serum on serotonin signaling was assessed using the human osteoblastic cell line Saos2, evaluating levels of phospho-CREB by Western immunoblots. Serotonin serum levels were significantly lower in patients with AS compared with healthy subjects (mean ± SEM ng/mL 122.9 ± 11.6 versus 177.4 ± 24.58, p = 0.038) and patients with RA (mean ± SEM ng/mL 244.8 ± 37.5, p = 0.0004). Patients with AS receiving TNFα blockers had significantly lower serotonin levels compared with patients with AS not on such treatment (mean ± SEM ng/mL 95.8 ± 14.9 versus 149.2 ± 16.0, p = 0.019). Serotonin serum levels were inversely correlated with pCREB induction in osteoblast-like Saos-2 cells. Serotonin levels are low in patients with AS and decrease even further during anti-TNFα treatment. Differences in serotonin levels are shown to have a functional impact on osteoblast-like Saos-2 cells. Therefore, serotonin may be involved in new bone formation in AS.
Collapse
Affiliation(s)
- Kalliopi Klavdianou
- Division of Rheumatology, University of Patras Medical School, Patras University Hospital, Patras, Greece
| | - Stamatis-Nick Liossis
- Division of Rheumatology, University of Patras Medical School, Patras University Hospital, Patras, Greece
| | - Dionysios J Papachristou
- Department of Anatomy-Histology-Embryology, Laboratory of Bone and Soft Tissue Studies, University of Patras Medical School, Patras, Greece
| | - Georgios Theocharis
- Department of Gastroenterology, University of Patras Medical School, Patras University Hospital, Patras, Greece
| | - Chaido Sirinian
- Clinical and Molecular Oncology Laboratory, University of Patras Medical School, Patras University Hospital, Patras, Greece
| | - Anastasia Kottorou
- Clinical and Molecular Oncology Laboratory, University of Patras Medical School, Patras University Hospital, Patras, Greece
| | - Alexandra Filippopoulou
- Division of Rheumatology, University of Patras Medical School, Patras University Hospital, Patras, Greece
| | - Andrew P Andonopoulos
- Division of Rheumatology, University of Patras Medical School, Patras University Hospital, Patras, Greece
| | - Dimitrios Daoussis
- Division of Rheumatology, University of Patras Medical School, Patras University Hospital, Patras, Greece
| |
Collapse
|
24
|
Dimitrakopoulos FID, Kottorou A, Antonacopoulou AG, Makatsoris T, Kalofonos HP. Early-Stage Breast Cancer in the Elderly: Confronting an Old Clinical Problem. J Breast Cancer 2015; 18:207-17. [PMID: 26472970 PMCID: PMC4600684 DOI: 10.4048/jbc.2015.18.3.207] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2014] [Accepted: 07/20/2015] [Indexed: 01/06/2023] Open
Abstract
Breast cancer generally develops in older women and its incidence is continuing to increase with increasing age of the population. The pathology and biology of breast cancer seem to be different in the elderly, often resulting in the undertreatment of elderly patients and thus in higher rates of recurrence and mortal-ity. The aim of this review is to describe the differences in the biology and treatment of early breast cancer in the elderly as well as the use of geriatric assessment methods that aid decision-making. Provided there are no contraindications, the cornerstone of treatment should be surgery, as the safety and efficacy of surgical resection in elderly women have been well documented. Because most breast cancers in the elderly are hormone responsive, hormonal therapy remains the mainstay of systemic treatment in the adjuvant setting. The role of chemotherapy is limited to patients who test negative for hormone receptors and demonstrate an aggressive tumor profile. Although the prognosis of breast cancer patients has generally improved during the last few decades, there is still a demand for evidence-based optimization of therapeutic interventions in older patients.
Collapse
Affiliation(s)
| | - Anastasia Kottorou
- Division of Oncology, Department of Medicine, University of Patras Medical School, Patras, Greece
| | - Anna G Antonacopoulou
- Division of Oncology, Department of Medicine, University of Patras Medical School, Patras, Greece
| | - Thomas Makatsoris
- Division of Oncology, Department of Medicine, University of Patras Medical School, Patras, Greece
| | - Haralabos P Kalofonos
- Division of Oncology, Department of Medicine, University of Patras Medical School, Patras, Greece
| |
Collapse
|
25
|
Dimitrakopoulos F, Antonacopoulou A, Kottorou A, Marousi S, Koukourikou I, Panagopoulos N, Scopa C, Papadaki H, Dougenis D, Kalofonos H. 226 Genetic variations of NF-κB2 are associated with overall survival of non-small cell lung cancer (NSCLC) patients. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30113-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
26
|
Dimitrakopoulos FID, Antonacopoulou AG, Kottorou A, Marousi S, Koukourikou I, Kalofonou M, Panagopoulos N, Scopa C, Dougenis D, Papadaki H, Papavassiliou AG, Kalofonos HP. Variant of BCL3 gene is strongly associated with five-year survival of non-small-cell lung cancer patients. Lung Cancer 2015; 89:311-9. [PMID: 26122346 DOI: 10.1016/j.lungcan.2015.06.006] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2015] [Revised: 05/18/2015] [Accepted: 06/11/2015] [Indexed: 01/15/2023]
Abstract
OBJECTIVES BCL3, a known atypical IκB family member, has been documented to be upregulated in hematological malignancies and in some solid tumors, functioning as a crucial player in tumor development. Recently, rs8100239, a tag-Single Nucleotide Polymorphism (SNP) in BCL3 (T>A) has been identified, but there are no data regarding its involvement in non-small-cell lung cancer (NSCLC) initiation and progression. MATERIALS AND METHODS To study the possible association of BCL3 with NSCLC, 268 patients and 279 healthy controls were genotyped for rs8100239. Moreover, BCL3 protein expression was also investigated in 112 NSCLC cases through an immunohistochemical analysis. RESULTS NSCLC patients with AA genotype displayed significantly worse prognosis compared to T allele carriers (P<0.001), who had less frequent intermediate nuclear BCL3 expression (P=0.042). In addition, overexpression of BCL3 was detected in tumor specimens, compared to normal tissue (P<0.001). Furthermore, BCL3 protein levels were associated with five-year survival (P=0.039), maximum diameter of lesion (P=0.012), grade (P=0.002) and relapse frequency (P=0.041). CONCLUSIONS The present study is the first to show a relationship between the genetic variation rs8100239 of BCL3 and cancer patients' survival. It also represents the first quantitative evaluation of BCL3 expression in NSCLC. Our findings indicate that rs8100239 may be considered as a novel prognostic indicator, demonstrating also the overexpression of BCL3 protein in NSCLC and implicating this pivotal molecule in the pathogenesis of NSCLC.
Collapse
Affiliation(s)
| | - Anna G Antonacopoulou
- Molecular Oncology Laboratory, Division of Oncology, Department of Internal Medicine, Medical School, University of Patras, Greece
| | - Anastasia Kottorou
- Molecular Oncology Laboratory, Division of Oncology, Department of Internal Medicine, Medical School, University of Patras, Greece
| | - Stella Marousi
- Molecular Oncology Laboratory, Division of Oncology, Department of Internal Medicine, Medical School, University of Patras, Greece
| | - Ioulia Koukourikou
- Molecular Oncology Laboratory, Division of Oncology, Department of Internal Medicine, Medical School, University of Patras, Greece
| | - Melpomeni Kalofonou
- Molecular Oncology Laboratory, Division of Oncology, Department of Internal Medicine, Medical School, University of Patras, Greece
| | | | - Chrisoula Scopa
- Department of Pathology, Medical School, University of Patras, Greece
| | - Dimitrios Dougenis
- Department of Cardiothoracic Surgery, Medical School, University of Patras, Greece
| | - Helen Papadaki
- Department of Anatomy, Medical School, University of Patras, Greece
| | | | - Haralabos P Kalofonos
- Molecular Oncology Laboratory, Division of Oncology, Department of Internal Medicine, Medical School, University of Patras, Greece.
| |
Collapse
|
27
|
Constantinopoulos P, Michalaki M, Kottorou A, Habeos I, Psyrogiannis A, Kalfarentzos F, Kyriazopoulou V. Cortisol in tissue and systemic level as a contributing factor to the development of metabolic syndrome in severely obese patients. Eur J Endocrinol 2015; 172:69-78. [PMID: 25336506 DOI: 10.1530/eje-14-0626] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
CONTEXT Adrenal and extra-adrenal cortisol production may be involved in the development of metabolic syndrome (MetS). OBJECTIVE To investigate the activity of the hypothalamic-pituitary-adrenal (HPA) axis and the expression of HSD11B1, nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptors) α (NR3C1α) and β (NR3C1β) in the liver, subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) of severely obese patients with and without MetS. METHODS The study included 37 severely obese patients (BMI ≥ 40 kg/m(2)), 19 with MetS (MetS+ group) and 18 without (MetS- group), studied before and during bariatric surgery. Before the day of surgery, urinary free cortisol (UFC) and diurnal variation of serum and salivary cortisol were estimated. During surgery, biopsies of the liver, VAT and SAT were obtained. The expression of HSD11B1, NR3C1α and NR3C1β was evaluated by RT-PCR. RESULTS UFC and area under the curve for 24-h profiles of serum and salivary cortisol were lower in the MetS- group. In the MetS- group, mRNA levels of HSD11B1 in liver exhibited a negative correlation with liver NR3C1α (LNR3C1α) and VAT expression of HSD11B1 was lower than the MetS+ group. CONCLUSIONS We observed a downregulation of the NR3C1α expression and lower VAT mRNA levels of HSD11B1 in the MetS- group, indicating a lower selective tissue cortisol production and action that could protect these patients from the metabolic consequences of obesity. In the MetS- group, a lower activity of the HPA axis was also detected. Taken together, cortisol in tissue and systematic level might play a role in the development of MetS in severely obese patients.
Collapse
Affiliation(s)
- Petros Constantinopoulos
- Division of EndocrinologyDiabetes and Metabolic Diseases, Department of Internal MedicineDivision of Nutritional Support and Morbid ObesityDepartment of SurgeryMolecular Oncology LaboratoryMedical School, University of Patras, 26500 Patras, Greece
| | - Marina Michalaki
- Division of EndocrinologyDiabetes and Metabolic Diseases, Department of Internal MedicineDivision of Nutritional Support and Morbid ObesityDepartment of SurgeryMolecular Oncology LaboratoryMedical School, University of Patras, 26500 Patras, Greece
| | - Anastasia Kottorou
- Division of EndocrinologyDiabetes and Metabolic Diseases, Department of Internal MedicineDivision of Nutritional Support and Morbid ObesityDepartment of SurgeryMolecular Oncology LaboratoryMedical School, University of Patras, 26500 Patras, Greece
| | - Ioannis Habeos
- Division of EndocrinologyDiabetes and Metabolic Diseases, Department of Internal MedicineDivision of Nutritional Support and Morbid ObesityDepartment of SurgeryMolecular Oncology LaboratoryMedical School, University of Patras, 26500 Patras, Greece
| | - Agathoklis Psyrogiannis
- Division of EndocrinologyDiabetes and Metabolic Diseases, Department of Internal MedicineDivision of Nutritional Support and Morbid ObesityDepartment of SurgeryMolecular Oncology LaboratoryMedical School, University of Patras, 26500 Patras, Greece
| | - Fotios Kalfarentzos
- Division of EndocrinologyDiabetes and Metabolic Diseases, Department of Internal MedicineDivision of Nutritional Support and Morbid ObesityDepartment of SurgeryMolecular Oncology LaboratoryMedical School, University of Patras, 26500 Patras, Greece
| | - Venetsana Kyriazopoulou
- Division of EndocrinologyDiabetes and Metabolic Diseases, Department of Internal MedicineDivision of Nutritional Support and Morbid ObesityDepartment of SurgeryMolecular Oncology LaboratoryMedical School, University of Patras, 26500 Patras, Greece
| |
Collapse
|
28
|
Dimitrakopoulos F, Antonacopoulou A, Kottorou A, Maroussi S, Koukourikou I, Scopa C, Papadaki H, Kalofonos H. 888 NFkB2 Intron 8 G/T Polymorphism in NSCLC Patients – a New Risk and Prognostic Factor. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)71520-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
29
|
Antonacopoulou A, Mathiopoulou A, Dimitrakopoulos F, Kottorou A, Scopa C, Kalofonos H. 6125 POSTER Two Polymorphisms of the Endothelin Axis in Colorectal Cancer. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)71770-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
30
|
Antonacopoulou AG, Floratou K, Bravou V, Kottorou A, Dimitrakopoulos FI, Marousi S, Stavropoulos M, Koutras AK, Scopa CD, Kalofonos HP. The survivin -31 snp in human colorectal cancer correlates with survivin splice variant expression and improved overall survival. Cell Oncol (Dordr) 2011; 34:381-91. [PMID: 21538024 DOI: 10.1007/s13402-011-0038-4] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/09/2010] [Indexed: 10/18/2022] Open
Abstract
BACKGROUND Survivin is involved in the regulation of cell division and survival, two key processes in cancer. The majority of studies on survivin in colorectal cancer (CRC) have focused on protein expression and less is known about the expression of survivin splicing variants or survivin gene polymorphisms in CRC. In the present study, the mRNA levels of the five known isoforms of survivin as well as survivin protein were assessed in matched normal and neoplastic colorectal tissue. Moreover, the 9386 C/T and -31 G/C polymorphisms were investigated. METHODS Quantitative RT-PCR was used to assess mRNA levels in fresh/frozen tissue samples. Protein levels were immunohistochemically evaluated on formalin-fixed paraffin-embedded tissue sections. Individuals were genotyped using real time PCR. RESULTS Expression of all 5 survivin splice variants as well as survivin protein was elevated in colorectal carcinomas compared to normal tissue. Specific splice variant expression differentially correlated with clinicopathological parameters. Furthermore, both snps correlated with splice variant levels or their ratios in colorectal carcinomas while the -31 G/C snp may be related to CRC development and improved overall survival. CONCLUSION Our results support a role of survivin in colorectal carcinogenesis while the -31 G/C snp may constitute a marker of survival.
Collapse
|
31
|
Dimitrakopoulos FID, Papadaki H, Antonacopoulou AG, Kottorou A, Gotsis AD, Scopa C, Kalofonos HP, Mouzaki A. Association of FOXP3 expression with non-small cell lung cancer. Anticancer Res 2011; 31:1677-1683. [PMID: 21617226] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
BACKGROUND/AIM Lung cancer is rarely cured by current therapeutic approaches. Although numerous studies have implicated FOXP3 positive regulatory T-cells in cancer pathogenesis, the role of FOXP3 in lung cancer pathogenesis remains unkown. MATERIALS AND METHODS Using immunohistochemistry FOXP3 expression was determined in 44 NSCLC tissue specimens, 20 samples from adjacent non neoplastic lung parenchyma and 5 normal lung tissue specimens. RESULTS FOXP3 immunostaining was always nuclear in both tumor and non-neoplastic adjacent tissues. FOXP3 was also detected at lower levels in normal bronchial epithelium. Moreover, FOXP3 expression in cancer cells correlated with lymphocytic FOXP3-immunopositivity and the presence of lymph node metastasis. FOXP3 lymphocytic expression was also negatively associated with the age of the patients. CONCLUSION FOXP3 is overexpressed in NSCLC cells and tumor-infiltrating lymphocytes. This study provides evidence that lymphocytic FOXP3 expression may be age related and that tumor FOXP3 expression is correlated with lymph node metastasis.
Collapse
MESH Headings
- Adenocarcinoma/metabolism
- Adenocarcinoma/pathology
- Adult
- Aged
- Aged, 80 and over
- Carcinoma, Large Cell/metabolism
- Carcinoma, Large Cell/pathology
- Carcinoma, Non-Small-Cell Lung/metabolism
- Carcinoma, Non-Small-Cell Lung/pathology
- Carcinoma, Squamous Cell/metabolism
- Carcinoma, Squamous Cell/pathology
- Female
- Forkhead Transcription Factors/metabolism
- Humans
- Immunoenzyme Techniques
- Lung Neoplasms/metabolism
- Lung Neoplasms/pathology
- Lymphatic Metastasis
- Lymphocytes, Tumor-Infiltrating/immunology
- Lymphocytes, Tumor-Infiltrating/metabolism
- Male
- Middle Aged
- Neoplasm Staging
- Prognosis
- T-Lymphocytes, Regulatory/immunology
- T-Lymphocytes, Regulatory/metabolism
Collapse
|
32
|
Antonacopoulou AG, Floratou K, Bravou V, Kottorou A, Dimitrakopoulos FI, Marousi S, Stavropoulos M, Koutras AK, Scopa CD, Kalofonos HP. The survivin -31 snp in human colorectal cancer correlates with survivin splice variant expression and improved overall survival. Anal Cell Pathol (Amst) 2011; 33:177-89. [PMID: 20978324 PMCID: PMC4605658 DOI: 10.3233/acp-clo-2010-0537] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Background: Survivin is involved in the regulation of cell division and survival, two key processes in cancer. The majority of studies on survivin in colorectal cancer (CRC) have focused on protein expression and less is known about the expression of survivin splicing variants or survivin gene polymorphisms in CRC. In the present study, the mRNA levels of the five known isoforms of survivin as well as survivin protein were assessed in matched normal and neoplastic colorectal tissue. Moreover, the 9386C/T and −31G/C polymorphisms were investigated. Methods: Quantitative RT-PCR was used to assess mRNA levels in fresh/frozen tissue samples. Protein levels were immunohistochemically evaluated on formalin-fixed paraffin-embedded tissue sections. Individuals were genotyped using real time PCR. Results: Expression of all 5 survivin splice variants as well as survivin protein was elevated in colorectal carcinomas compared to normal tissue. Specific splice variant expression differentially correlated with clinicopathological parameters. Furthermore, both snps correlated with splice variant levels or their ratios in colorectal carcinomas while the −31G/C snp may be related to CRC development and improved overall survival. Conclusion: Our results support a role of survivin in colorectal carcinogenesis while the −31G/C snp may constitute a marker of survival.
Collapse
|
33
|
Kottorou A, Antonacopoulou A, Tsamandas A, Grivas P, Scopa C, Kalofonos H. 764 Increased expression of NFY-C (Nuclear Factor Y, subunit C) and RORA (Retinoic acid receptor-related Orphan Receptor Alpha) in colorectal adenocarcinoma. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)71560-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
34
|
Dimitrakopoulos F, Antonacopoulou A, Maroussi S, Kottorou A, Scopa C, Kalofonos H. 765 An intron 8 polymorphism G/T of NFKB2 gene is associated with NSCLC. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)71561-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
35
|
Antonacopoulou AG, Argyriou AA, Scopa CD, Kottorou A, Kominea A, Peroukides S, Kalofonos HP. Integrin beta-3 L33P: a new insight into the pathogenesis of chronic oxaliplatin-induced peripheral neuropathy? Eur J Neurol 2010; 17:963-8. [DOI: 10.1111/j.1468-1331.2010.02966.x] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
36
|
Dimitrakopoulos F, Antonacopoulou A, Maroussi S, Kottorou A, Scopa C, Kalofonos H. 9049 Intron 8 polymorphism G/T of NFkB2 gene: risk factor for non small cell lung carcinoma. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71762-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
37
|
Argyriou AA, Antonacopoulou AG, Scopa CD, Kottorou A, Kominea A, Peroukides S, Kalofonos HP. Liability of the Voltage-Gated Sodium Channel Gene SCN2A R19K Polymorphism to Oxaliplatin-Induced Peripheral Neuropathy. Oncology 2009; 77:254-6. [DOI: 10.1159/000236049] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2009] [Accepted: 06/08/2009] [Indexed: 11/19/2022]
|